dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Choudhury, Atish D. |
dc.contributor.author | Higano, Celestia |
dc.contributor.author | Cook, Natalie |
dc.contributor.author | Rathkopf, Dana E. |
dc.contributor.author | Wisinski, Kari |
dc.contributor.author | Martín Liberal, Juan Jesús |
dc.contributor.author | de Bono, Johann S |
dc.date.accessioned | 2022-09-08T11:41:04Z |
dc.date.available | 2022-09-08T11:41:04Z |
dc.date.issued | 2022-06-01 |
dc.identifier.citation | Choudhury AD, Higano CS, de Bono JS, Cook N, Rathkopf DE, Wisinski KB, et al. A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 Jun 1;28(11):2257–69. |
dc.identifier.issn | 1557-3265 |
dc.identifier.uri | https://hdl.handle.net/11351/8076 |
dc.description | Tumores sólidos avanzados; Inhibidor de PI3K beta/delta |
dc.language.iso | eng |
dc.publisher | American Association for Cancer Research |
dc.relation.ispartofseries | Clinical Cancer Research;28(11) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Càncer - Tractament |
dc.subject | Fosfodiesterases - Inhibidors |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Phosphodiesterase Inhibitors |
dc.title | A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1158/1078-0432.CCR-21-3087 |
dc.subject.decs | neoplasias |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | inhibidores de fosfodiesterasas |
dc.relation.publishversion | https://doi.org/10.1158/1078-0432.CCR-21-3087 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Choudhury AD] Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. [Higano CS] Department of Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, Washington. [de Bono JS] Drug Development Unit, The Institute of Cancer Research and Royal Marsden, London, United Kingdom. [Cook N] The Christie NHS Foundation Trust and The University of Manchester, Manchester, United Kingdom. [Rathkopf DE] Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, New York. [Wisinski KB] Carbone Cancer Center, University of Wisconsin–Madison, Madison, Wisconsin. [Martin-Liberal J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 35247924 |
dc.identifier.wos | 000809230200001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |